studies

hepatocell cancer (HCC), immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 459, 2019 0.85 [0.71; 1.01] IMbrave-150, 2020 0.58 [0.42; 0.80] KEYNOTE-240, 2020 0.78 [0.61; 1.00] 0.75[0.61; 0.92]CheckMate 459, 2019, IMbrave-150, 2020, KEYNOTE-240, 2020354%1,657moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 459, 2019 0.93 [0.79; 1.10] IMbrave-150, 2020 0.59 [0.46; 0.75] KEYNOTE-240, 2020 0.72 [0.57; 0.90] 0.74[0.56; 0.97]CheckMate 459, 2019, IMbrave-150, 2020, KEYNOTE-240, 2020380%1,657moderatenot evaluable DCRdetailed resultsKEYNOTE-240, 2020 1.44 [0.95; 2.19] 1.44[0.95; 2.19]KEYNOTE-240, 202010%413NAnot evaluable objective responses (ORR)detailed resultsCheckMate 459, 2019 2.42 [1.48; 3.94] IMbrave-150, 2020 2.77 [1.62; 4.73] KEYNOTE-240, 2020 4.83 [2.02; 11.57] 2.82[2.02; 3.93]CheckMate 459, 2019, IMbrave-150, 2020, KEYNOTE-240, 202030%1,657moderatenot evaluable AE (any grade)detailed resultsIMbrave-150, 2020 0.70 [0.14; 3.50] KEYNOTE-240, 2020 2.89 [1.23; 6.77] 1.69[0.44; 6.51]IMbrave-150, 2020, KEYNOTE-240, 2020257%898lownot evaluable AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.06 [0.72; 1.55] KEYNOTE-240, 2020 1.26 [0.83; 1.90] 1.15[0.87; 1.52]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable AE leading to death (grade 5)detailed resultsIMbrave-150, 2020 0.78 [0.33; 1.82] KEYNOTE-240, 2020 0.84 [0.24; 2.91] 0.80[0.40; 1.61]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMbrave-150, 2020 1.61 [0.88; 2.92] KEYNOTE-240, 2020 2.11 [1.08; 4.13] 1.81[1.16; 2.83]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.04 [1.32; 6.97] 3.04[1.32; 6.97]KEYNOTE-240, 202010%413NAnot evaluable SAE (any grade)detailed resultsIMbrave-150, 2020 1.38 [0.92; 2.07] 1.38[0.92; 2.07]IMbrave-150, 202010%485NAnot evaluable STRAE (grade 3-4)detailed resultsCheckMate 459, 2019 0.30 [0.22; 0.41] 0.30[0.22; 0.41]CheckMate 459, 201910%743NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-240, 2020 1.66 [1.09; 2.51] 1.66[1.09; 2.51]KEYNOTE-240, 202010%413NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.77 [1.36; 5.65] 2.77[1.36; 5.65]KEYNOTE-240, 202010%413NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 459, 2019 0.53 [0.28; 1.00] 0.53[0.28; 1.00]CheckMate 459, 201910%743NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.24 [0.02; 2.64] 0.24[0.02; 2.64]KEYNOTE-240, 202010%413NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.90 [0.14; 58.35] 2.90[0.14; 58.35]KEYNOTE-240, 202010%413NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.03; 7.71] 0.48[0.03; 7.71]KEYNOTE-240, 202010%413NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.09; 10.69] 0.96[0.09; 10.69]KEYNOTE-240, 202010%413NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dyspepsia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Eczema TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.45 [0.15; 14.03] 1.45[0.15; 14.03]KEYNOTE-240, 202010%413NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.88 [0.20; 74.00] 3.88[0.20; 74.00]KEYNOTE-240, 202010%413NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.75 [0.85; 16.64] 3.75[0.85; 16.64]KEYNOTE-240, 202010%413NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.45 [0.53; 11.36] 2.45[0.53; 11.36]KEYNOTE-240, 202010%413NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.24 [0.01; 7.16] 0.24[0.01; 7.16]KEYNOTE-240, 202010%413NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 5.87 [0.33; 105.85] 5.87[0.33; 105.85]KEYNOTE-240, 202010%413NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.12; 1.90] KEYNOTE-240, 2020 3.88 [0.20; 74.00] 0.89[0.13; 6.01]IMbrave-150, 2020, KEYNOTE-240, 2020238%898moderatenot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.16 [0.02; 1.51] 0.16[0.02; 1.51]IMbrave-150, 202010%485NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.07 [0.32; 3.53] KEYNOTE-240, 2020 0.42 [0.18; 0.97] 0.61[0.25; 1.49]IMbrave-150, 2020, KEYNOTE-240, 2020237%898lownot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.03; 7.71] 0.48[0.03; 7.71]KEYNOTE-240, 202010%413NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 1.05] KEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.16[0.02; 1.11]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.88 [0.20; 74.00] 3.88[0.20; 74.00]KEYNOTE-240, 202010%413NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] KEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.71[0.05; 9.27]IMbrave-150, 2020, KEYNOTE-240, 202020%898lownot evaluable Cough AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] KEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.32[0.02; 4.18]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.31 [0.09; 1.11] KEYNOTE-240, 2020 2.90 [0.14; 58.35] 0.62[0.08; 4.71]IMbrave-150, 2020, KEYNOTE-240, 2020245%898moderatenot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.34 [0.12; 1.01] KEYNOTE-240, 2020 0.64 [0.14; 2.88] 0.42[0.18; 1.02]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 2.61] 0.12[0.01; 2.61]IMbrave-150, 202010%485NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.63 [0.14; 2.84] KEYNOTE-240, 2020 0.12 [0.01; 2.65] 0.46[0.12; 1.77]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Epistaxis AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.75 [0.24; 2.34] KEYNOTE-240, 2020 1.70 [0.35; 8.29] 0.99[0.39; 2.49]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Hypertension AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.29 [0.73; 2.28] 1.29[0.73; 2.28]IMbrave-150, 202010%485NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.39 [0.61; 3.18] KEYNOTE-240, 2020 1.90 [0.91; 3.94] 1.66[0.96; 2.86]IMbrave-150, 2020, KEYNOTE-240, 202020%898lownot evaluable Increased ALT AE (grade 3-4)detailed resultsIMbrave-150, 2020 2.91 [0.64; 13.19] KEYNOTE-240, 2020 2.11 [0.70; 6.39] 2.36[0.97; 5.77]IMbrave-150, 2020, KEYNOTE-240, 202020%898lownot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMbrave-150, 2020 7.75 [0.44; 135.83] 7.75[0.44; 135.83]IMbrave-150, 202010%485NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.03; 7.61] KEYNOTE-240, 2020 0.96 [0.09; 10.69] 0.71[0.11; 4.37]IMbrave-150, 2020, KEYNOTE-240, 202020%898lownot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.02 [0.00; 0.28] 0.02[0.00; 0.28]IMbrave-150, 202010%485NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsIMbrave-150, 2020 4.86 [0.62; 38.30] 4.86[0.62; 38.30]IMbrave-150, 202010%485NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] KEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.71[0.05; 9.27]IMbrave-150, 2020, KEYNOTE-240, 202020%898lownot evaluable Pyrexia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.17; 5.23] KEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.12[0.25; 4.99]IMbrave-150, 2020, KEYNOTE-240, 202020%898moderatenot evaluable Rash AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.06 [0.00; 1.10] KEYNOTE-240, 2020 1.93 [0.09; 43.05] 0.32[0.01; 10.00]IMbrave-150, 2020, KEYNOTE-240, 2020261%898moderatenot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.23; 3.84] 0.95[0.23; 3.84]IMbrave-150, 202010%485NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.09; 10.54] 0.95[0.09; 10.54]IMbrave-150, 202010%485NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-01 16:19 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 234,40,132,131,133 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons